Hybio Pharmaceutical Co.Ltd(300199) replied to the inquiry letter of Shenzhen stock exchange that in parallel with other covid-19 specific drug R & D projects developed based on polypeptide technology platform in China, the polypeptide nasal spray project of the company has lasted five months since the signing of the patent authorization agreement in November 2021. According to the current progress, it is carrying out animal in vivo pharmacodynamics research, in vivo pharmacology and toxicology research, safety evaluation research and sample production under GMP conditions. Based on the above research and development progress, the company believes that covid-19 nasal spray drug is accurately described as "in the stage of rapid development".
© China Stock Market News